News
ENTA
5.86
-0.34%
-0.02
Weekly Report: what happened at ENTA last week (0317-0321)?
Weekly Report · 3d ago
Weekly Report: what happened at ENTA last week (0310-0314)?
Weekly Report · 03/17 09:27
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium
Barchart · 03/12 06:00
Weekly Report: what happened at ENTA last week (0303-0307)?
Weekly Report · 03/10 09:28
Weekly Report: what happened at ENTA last week (0224-0228)?
Weekly Report · 03/03 09:28
Based on the provided financial report, the title of the article is: "ENANTA PHARMACEUTICALS, INC. Quarterly Report (Form 10-Q) for the quarterly period ended December 31, 2024
Press release · 03/02 09:42
Enanta Pharmaceuticals: Hold Rating Amid Delayed Launches and Strategic Advancements
TipRanks · 02/25 05:55
The 1-Minute Market Report February 22, 2025
Seeking Alpha · 02/24 12:21
Weekly Report: what happened at ENTA last week (0217-0221)?
Weekly Report · 02/24 09:28
Weekly Report: what happened at ENTA last week (0210-0214)?
Weekly Report · 02/17 09:27
Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade
NASDAQ · 02/14 17:00
Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Shares Bounce 55% But Its Business Still Trails The Industry
Simply Wall St · 02/14 10:44
Thursday 2/13 Insider Buying Report: BPRN, ENTA
NASDAQ · 02/13 19:24
Enanta Pharmaceuticals (ENTA) Receives a Buy from Evercore ISI
TipRanks · 02/13 05:44
Enanta Pharmaceuticals Advances in Virology and Immunology
TipRanks · 02/13 03:55
Enanta CEO buys $256K in common stock
TipRanks · 02/13 02:16
Based on the provided financial report, the title of the article is: "ENANTA PHARMACEUTICALS, INC. Quarterly Report (Form 10-Q) for the quarterly period ended December 31, 2024
Press release · 02/12 21:11
Enanta Pharmaceuticals First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St · 02/12 11:11
Enanta Pharmaceuticals Price Target Maintained With a $21.00/Share by JMP Securities
Dow Jones · 02/11 15:52
JMP Securities Reiterates Market Outperform on Enanta Pharma, Maintains $21 Price Target
Benzinga · 02/11 15:43
More
Webull provides a variety of real-time ENTA stock news. You can receive the latest news about Enanta Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ENTA
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.